Patent application number | Description | Published |
20090285862 | METHODS AND COMPOSITION FOR TREATMENT OF INFLAMMATORY PAIN - The present invention relates to the field of pain management, and in particular, the management of inflammatory pain without inducing overt sedation. The present invention features compositions and treatments for inflammatory pain comprising the administration of an amount of an neurokinin (NK) antagonist in combination with a neuronal excitation inhibitor. | 11-19-2009 |
20100316678 | COMBINATION METHODS AND COMPOSITIONS FOR TREATMENT OF NEUROPATHIC PAIN - The present invention relates generally to the field of pain management, and in particular, the management of neuropathic pain. The present invention further provides methods and compositions that treat, alleviate, prevent, diminish or otherwise ameliorate the symptoms of neuropathic pain without inducing overt sedation. The present invention also contemplates combination therapy using one or more NK antagonists in combination with one or more compounds which decrease or inhibit neuronal excitation in the treatment of pain in association with the treatment of a particular disease condition or pathology. | 12-16-2010 |
20110129508 | METHODS AND COMPOSITIONS FOR THE MANAGEMENT OF PAIN USING OMEGA-CONOTOXINS - The present invention relates to the management of pain (nociceptive, neuropathic, inflammatory and disease related pains), using omega-conotoxins alone or in combination with neuronal excitation inhibitors (analgesics). The invention in particular provides methods, protocols, compositions and devices which treat, alleviate, prevent, diminish or otherwise ameliorate the sensation of pain. | 06-02-2011 |
20110224147 | METHODS AND COMPOSITIONS - A method for inducing an analgesic response to inflammatory or neuropathic pain by administration of 1-(2-(4-chlorophenyl)-2-hydroxy)ethyl-4-(3,5-bis(1,1 dimethyl)-4-hydroxyphenyl)methyl piperazine, also called CNSB002 or AM-36, either alone or with an opioid and/or a neurokinin (NK) antagonist. | 09-15-2011 |
20120316146 | ANAESTHETIC FORMULATION - The present invention relates generally to the field of drug delivery systems for neuroactive steroid anaesthetic agents. More particularly, anaesthetic and sedative formulations are provided in the form of host/guest preparations comprising one or more neuroactive steroid anaesthetics and a cyclodextrin. Particular cyclodextrins contemplated include sulfoalkyl ether cyclodextrins and modified forms thereof. | 12-13-2012 |
20140066417 | ANAESTHETIC FORMULATION - The present invention relates generally to the field of drug delivery systems for neuroactive steroid anaesthetic agents. More particularly, anaesthetic and sedative formulations are provided in the form of host/guest preparations comprising one or more neuroactive steroid anaesthetics and a cyclodextrin. Particular cyclodextrins contemplated include sulfoalkyl ether cyclodextrins and modified forms thereof. | 03-06-2014 |